A production process for enhancing the immune function of pet food and its application

By employing a process of pre-regulating redox potential, gradient dispersion and encapsulation, and dynamic switching sterilization, combined with targeted repair and maturation during the residual heat window, the problem of thermal damage and bioavailability of immune-active components in pet wet food cans has been solved. This achieves stable protection and efficient release of immune-active components, thereby enhancing the immune function of pet food.

CN123100744APending Publication Date: 2026-11-17SUZHOU JIHE VITAL BIOLOGY TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611479159.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-22
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In existing pet wet food canning processes, immune-active components such as lactoferrin, immunoglobulins, and bioactive peptides are prone to conformational changes or irreversible denaturation during high-temperature sterilization, leading to a decline or loss of immune regulation function. Furthermore, they are easily decomposed and destroyed in the highly acidic environment of the stomach, limiting their bioavailability.

Method used

By employing a process of redox potential pre-regulation, gradient dispersion and embedding, and dynamic switching sterilization, combined with targeted repair and maturation during the residual heat window after sterilization, a core-shell dispersion structure is formed, constructing a gastrointestinal targeted release system that protects the activity of immune-active components and improves their bioavailability.

Benefits of technology

It effectively reduces the degree of thermal damage to immune-active ingredients, improves their activity retention rate and bioavailability, ensures stable release in the gastrointestinal tract, and enhances the immune function of pet food.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123100744A_ABST
    Figure CN123100744A_ABST
Patent Text Reader

Abstract

This invention discloses a production process and its application for enhancing the immune function of pet food, relating to the field of pet food technology. The process includes the following steps: lowering the redox potential of the matrix below the critical redox potential of the immune-active components; dissolving carbon dioxide in the matrix to create a slightly acidic environment; dynamically switching between a standard sterilization path and a low-temperature long-time compensation path for sterilization; targeted repair of the immune-active components; and maturation and shaping to obtain a wet food product that enhances the immune function of pet food. This invention, through the combined effects of redox potential pre-regulation, gradient dispersion and embedding, and dynamic sterilization switching, reduces the degree of thermal damage to the immune-active components during sterilization, thus helping to improve the activity retention rate of the immune-active components. Specifically, redox potential pre-regulation creates a reducing microenvironment in the matrix, reducing the tendency for oxidative damage to the immune-active components and thus avoiding excessive damage to the immune-active components from continuous high temperatures.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pet food technology, and in particular to a production process for enhancing the immune function of pet food and its application. Background Technology

[0002] Wet pet food, due to its high moisture content and palatability, has become an important category of pet food. To meet commercial aseptic requirements, wet food typically undergoes high-temperature, high-pressure sterilization. However, protein-based immunomodulatory components such as lactoferrin, immunoglobulins, and bioactive peptides are heat-sensitive and are prone to spatial conformational changes or irreversible denaturation under high-temperature sterilization conditions, leading to a decrease or loss of their immunomodulatory function.

[0003] In existing production processes, the aforementioned immune-active components are mostly introduced into the wet food matrix through direct addition or simple physical mixing, lacking systematic protection methods for these components throughout the entire processing. Furthermore, existing wet food canning production lines typically use rapid cooling to terminate the reaction after sterilization, failing to utilize the residual heat after sterilization and thus failing to effectively intervene in any structural damage that has already occurred. Once protein-based immune-active components enter the pet's gastrointestinal tract, they are easily decomposed and destroyed in the highly acidic environment of the stomach, making it difficult for them to effectively reach the intestines and be absorbed and utilized, thus limiting their bioavailability. Summary of the Invention

[0004] The purpose of this invention is to provide a production process and its application for enhancing the immune function of pet food, so as to solve the problems mentioned in the background art.

[0005] To achieve the above objectives, the present invention provides the following technical solution: a production process for enhancing the immune function of pet food, comprising the following steps:

[0006] The redox potential of the wet pet food matrix containing immune-active ingredients is pre-adjusted so that the redox potential of the matrix is ​​lower than the critical redox potential of the immune-active ingredients.

[0007] The immunoactive components are encapsulated in a microgel precursor in a gradient dispersion manner to form a core-shell dispersion structure.

[0008] The filled tanks undergo headspace displacement and pre-equilibrium treatment to dissolve carbon dioxide in the matrix and create a slightly acidic environment.

[0009] Based on the feedback of the activity decay rate of the immune active components, sterilization is dynamically switched between the standard sterilization path and the low-temperature long-time compensation path.

[0010] During the residual heat window after sterilization, the immune-active components are targeted for repair.

[0011] After maturation and shaping, a wet food product that enhances the immune function of pet food is obtained.

[0012] Preferably, the pre-adjustment of the redox potential includes:

[0013] A reducing agent is added to the matrix, and an inert gas is introduced during the chopping process for bubble deoxygenation.

[0014] The matrix redox potential is monitored in real time. When the matrix redox potential is lower than the critical redox potential by a preset safety margin, the pre-adjustment is deemed qualified.

[0015] Preferably, the encapsulation of the immunologically active ingredient in the microgel precursor in a gradient dispersion manner includes:

[0016] The first stage of high-shear treatment involves dispersing gel-forming protein substances in the matrix to form microgel precursors.

[0017] The second stage of low-shear treatment involves introducing and encapsulating the immunoactive components within the microgel precursor to form the core-shell dispersion structure.

[0018] The particle size distribution characteristic value of the slurry is monitored online. When the particle size distribution characteristic value is within a preset protection range, the directional dispersion is deemed qualified.

[0019] Preferably, the headspace atmosphere replacement and pre-equilibration treatment includes:

[0020] The filled tanks are subjected to a three-stage gas replacement process: vacuuming, filling with nitrogen to atmospheric pressure, and then filling with carbon dioxide to a preset pressure.

[0021] After sealing, maintain a preset pre-equilibrium time to allow carbon dioxide to fully dissolve in the matrix and form a slightly acidic environment before proceeding to the sterilization process.

[0022] Preferably, the dynamic switching sterilization based on activity decay rate feedback includes:

[0023] In the sterilization platform section and the heat preservation section, the activity decay rate of the immunologically active component is compared with a preset threshold, and the path is selected based on the comparison result:

[0024] When the activity decay rate is not higher than a preset threshold, the standard sterilization path is maintained;

[0025] When the activity decay rate is higher than a preset threshold, the system switches to the low-temperature long-term compensation path and simultaneously replenishes the headspace of the tank with inert protective gas.

[0026] Preferably, the activity decay rate is estimated by real-time monitoring of changes in parameters inside the sterilization tank during the sterilization process;

[0027] The standard sterilization path is to sterilize at a first sterilization temperature and a first holding time, and the low-temperature long-time compensation path is to sterilize at a second sterilization temperature lower than the first sterilization temperature and a second holding time longer than the first holding time, with the equivalent sterilization values ​​being the same.

[0028] The low-temperature long-term compensation path also includes performing pulsed steam injection during the heat preservation period. The pulsed steam injection is a cyclical operation in which steam is injected into the sterilizer at preset time intervals to raise the temperature instantaneously, and then the pressure is released instantaneously to lower the temperature.

[0029] Preferably, the targeted repair during the residual heat window after sterilization includes:

[0030] The cooling rate of the first cooling stage is controlled to be lower than that of the second cooling stage; wherein, the first cooling stage is to reduce the temperature from the sterilization peak temperature to the first target temperature, and the second cooling stage is to reduce the temperature from the first target temperature to room temperature;

[0031] During the first cooling phase, the residual heat window period is maintained, and / or the carbon dioxide dissolved in the matrix during the pre-equilibrium phase is used in combination with residual reducing substances to promote the repair of sublethal structural damage of immune active components.

[0032] When the tank surface temperature drops below the second target temperature, switch to the second cooling stage to accelerate cooling.

[0033] Preferably, the aging and shaping includes:

[0034] Place the container, cooled to room temperature, at the preset ambient temperature for a preset curing time;

[0035] During the maturation process, the microgel cores in the core-shell dispersion structure shrink and densify. Simultaneously, due to the decrease in temperature during maturation, the supersaturated carbon dioxide inside the microgel cores escapes, and the microgel cores shrink and densify to form a microporous structure, thus constructing a gastrointestinal targeted release structure.

[0036] After the curing process is completed, the pressure inside the tank and the stability of the tank structure are tested. When the pressure inside the tank is within the preset slightly positive pressure range and the structural stability meets the preset conditions, the curing process is deemed qualified.

[0037] Preferred options also include:

[0038] The product after maturation and shaping was subjected to in vitro simulated digestion assays to obtain the bioavailability of the immune-active components.

[0039] The biological accessibility rate is compared with a target threshold. When the biological accessibility rate is lower than the target threshold, the deviation is fed back to the preceding steps and the corresponding parameters are corrected. The preceding steps include at least one of the following: a preset target value for pre-adjusting redox potential, a shearing parameter for gradient dispersion and embedding, and a preset threshold for dynamically switching sterilization.

[0040] The application of a manufacturing process in the preparation of wet food products that enhance the immune function of pets, said wet food products including mousse-like, meat chunk-like, or soup-type pet canned food.

[0041] The technical effects and advantages of this invention are as follows:

[0042] (1) This invention reduces the degree of thermal damage to immunoactive components during sterilization by combining redox potential pre-regulation, gradient dispersion and embedding, and dynamic switching sterilization, which helps to improve the activity retention rate of immunoactive components. Among them, redox potential pre-regulation puts the matrix in a reducing microenvironment, reducing the tendency of immunoactive components to be oxidized and damaged; the core-shell dispersion structure formed by gradient dispersion and embedding plays a physical isolation and protection role for immunoactive components; dynamic switching sterilization switches between the standard sterilization path and the low temperature long-term compensation path according to the feedback of the activity decay rate, thereby avoiding excessive damage to immunoactive components caused by continuous high temperature.

[0043] (2) By controlling the cooling rate of the first cooling stage after sterilization, the present invention utilizes the residual heat window period to provide sufficient time for the residual reducing substances in the matrix to interact with the immunoactive components, thereby mitigating the degree of thermal denaturation and helping to reduce irreversible structural damage to the immunoactive components. In the first cooling stage, the carbon dioxide dissolved in the matrix during the pre-equilibrium stage works with the residual reducing substances to maintain the reducing environment of the matrix and slow down the oxidative damage process of the immunoactive components. Thus, the relatively slow cooling process allows the above chemical reaction to proceed fully, rather than being interrupted by a sudden drop in temperature.

[0044] (3) In the process of ripening and shaping, the microgel core undergoes uneven shrinkage, the outer shell tends to become dense, and the core region is squeezed outward due to the displacement of dissolved gas and water, forming a microporous structure in the core region, thus constructing a gastrointestinal targeted release system. This allows the immune active ingredients to remain relatively stable in the acidic environment of the stomach and to be gradually released in the neutral to weakly alkaline environment of the intestine and under the action of digestive enzymes, which helps to improve their bioavailability. The microporous structure is formed by the physical shrinkage process of the microgel core during ripening, so there is no need to add additional chemical pore-forming agents, and it is compatible with the production process of wet grain canned food. Attached Figure Description

[0045] The accompanying drawings are provided to further illustrate the invention and form part of the specification. They are used together with the embodiments of the invention to explain the invention, but do not constitute a limitation thereof. In the drawings:

[0046] Figure 1 This is a schematic diagram of the production process of the present invention. Detailed Implementation

[0047] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0048] This invention provides, for example Figure 1 The production process for enhancing the immune function of pet food, as shown, includes the following steps: pre-adjusting the redox potential of a wet pet food matrix containing immune-active ingredients; encapsulating the immune-active ingredients in a microgel precursor in a gradient dispersion manner to form a core-shell dispersion structure; subjecting the filled can to headspace atmosphere replacement and pre-equilibration treatment; dynamically switching between a standard sterilization path and a low-temperature long-time compensation path based on feedback of the activity decay rate of the immune-active ingredients; directionally repairing the immune-active ingredients during the residual heat window after sterilization; and obtaining a wet food product that enhances the immune function of pet food after maturation and shaping.

[0049] The wet food matrix used in this invention comprises animal-derived protein slurry, plant-based additives, water, and optional edible colloids. The animal-derived protein slurry can be prepared from chicken, fish, beef, duck, or a combination thereof through mincing and chopping. The immunomodulatory components are selected from at least one of lactoferrin, immunoglobulins, β-glucan, post-biotics, and bioactive peptides, with the specific type and amount determined according to the product's functional positioning. The reducing agent is selected from at least one of cysteine, ascorbate palmitate, and glutathione-enriched yeast extract. The microgel precursor material is selected from at least one of collagen, gelatin, and soy protein isolate.

[0050] The equipment system used in this invention includes: a chopper with vacuum and inert gas bubbling interfaces for pre-adjusting the redox potential of the matrix; a high-shear homogenizer and a low-shear mixer for gradient dispersion and encapsulation of immunologically active ingredients; an automatic filling and sealing machine for quantitative filling and sealing of wet grains; a horizontal rotary autoclave or tunnel-type continuous sterilization equipment equipped with a real-time monitoring module for internal temperature and pressure, a headspace inflation system, and a pulsed steam injection module; a cooling section, which is a functional chamber surrounding the tank, with atomizing nozzles at its top for directional repair of residual heat during the sterilization window; and a cleanroom constant-temperature curing zone for product curing and shaping.

[0051] Example 1: Wet grain matrix raw materials and a reducing agent are added to a chopper, the chopping is started, and inert gas is introduced for bubbling deoxygenation. An online redox potential monitoring probe is installed inside the chopper to monitor the matrix's redox potential in real time. When the matrix's redox potential is lower than the critical redox potential of the immunoactive component by a preset safety margin, the pre-conditioning is deemed qualified, chopping is stopped, and the process proceeds to the next step. Through this step, the matrix is ​​placed in a reducing microenvironment, and the free thiol groups, disulfide bonds, and spatial conformation of the immunoactive component are pre-protected before subsequent heat treatment.

[0052] The matrix, pre-adjusted for redox potential, was transferred into a dispersion and embedding system, and staged shear control was employed.

[0053] The first stage is high-shear treatment. Gel-forming protein substances are dispersed in the matrix and formed microgel precursors under high shear.

[0054] The second stage is low-shear treatment. The immunologically active ingredient is added to the matrix containing the microgel precursor. Under low-shear conditions, the immunologically active ingredient is encapsulated inside the microgel precursor, forming a core-shell dispersion structure, in which the microgel precursor forms the outer shell and the immunologically active ingredient forms the core.

[0055] In the second stage, the particle size distribution characteristics of the slurry are monitored in real time using an online laser particle size monitoring device. When the particle size distribution characteristics are within the preset protection range, the directional dispersion is deemed qualified, the shearing is terminated, and the process proceeds to the filling stage. When the particle size distribution characteristics deviate from the preset protection range, the shearing rate or shearing duration is adjusted accordingly until the preset conditions are met.

[0056] The gradient-dispersed wet grain slurry is quantitatively filled into the tank using an automatic filling and sealing machine, leaving headspace. After filling, the tank undergoes a three-stage step gas replacement: first, a vacuum is created inside the tank; then, nitrogen is introduced to atmospheric pressure; and finally, carbon dioxide is introduced to a preset pressure. The tank is immediately sealed after gas replacement. The sealed tank then enters a pre-equilibration zone, where it is maintained for a preset pre-equilibration time to allow carbon dioxide to fully dissolve in the wet grain matrix, creating a slightly acidic environment. After pre-equilibration, the tank proceeds to the sterilization process.

[0057] The pre-equilibrated tank is placed in the sterilization equipment. The sterilization equipment is equipped with a headspace inflation system, including a main inflation pipe arranged along the inner wall of the sterilizer and inflation branch pipes corresponding to the headspace positions of the tank. The sterilization process is divided into a heating section, a plateau section, and a holding section.

[0058] In the sterilization platform and heat preservation sections, dynamic path selection is performed based on feedback from the activity decay rate of the immunologically active components. The activity decay rate is estimated by real-time monitoring of changes in parameters within the tank during sterilization. Specifically, the sterilization equipment is equipped with a tank pressure sensor and a matrix conductivity monitoring device. The system indirectly estimates the cumulative activity decay rate of the immunologically active components under the current sterilization path based on the comprehensive correlation between the tank pressure change trend and the matrix conductivity change trend. The pressure change trend reflects the degree of moisture vaporization and headspace gas expansion in the matrix, while the conductivity change trend reflects the degree of ionic group release during the thermal denaturation of the immunologically active components.

[0059] The estimated activity decay rate is compared with a preset threshold: when the activity decay rate is not higher than the preset threshold, the standard sterilization path is maintained, which involves sterilization at a first sterilization temperature and a first holding time; when the activity decay rate is higher than the preset threshold, the system automatically switches to a low-temperature long-time compensation path, which involves sterilization at a second sterilization temperature lower than the first sterilization temperature and a second holding time longer than the first holding time. The system adjusts the combination of the second sterilization temperature and the second holding time to ensure that the temperature-time integral value remains the same as the standard sterilization path. When switching to the low-temperature long-time compensation path, inert protective gas is supplied to the headspace inside the sterilizer through the gas supply branch pipe. The pressure control system of the sterilizer dynamically adjusts the pressure inside the sterilizer to maintain a stable sterilization environment, thereby inhibiting oxidative damage to the immunologically active components.

[0060] During the heat preservation period of the low-temperature long-term compensation path, the sterilization equipment performs a pulsed steam injection operation. Pulsed steam injection is a cyclical operation in which steam is injected into the sterilizer at preset time intervals to instantly raise the temperature, and then the pressure is instantly released through the pressure relief valve to allow the temperature to drop.

[0061] After sterilization, conventional rapid cooling is not immediately implemented; instead, a targeted repair phase is initiated during the residual heat window. This phase employs a two-stage cooling control system.

[0062] The first cooling stage involves reducing the temperature from the peak sterilization temperature to the first target temperature. During this stage, the cooling rate is controlled to be lower than that of the second cooling stage to maintain the residual heat window. In the first cooling stage, the tank is placed within the functional chamber of the cooling section. A mixture of atomized protective liquid containing the remediation substrate and inert carrier gas is injected into the functional chamber through atomizing nozzles located at the top of the chamber. The remediation substrate is selected from at least one of trehalose, glutamine, and magnesium ion compounds.

[0063] The mixed flow contacts the outer wall of the tank within the functional chamber. The atomized protective liquid forms a thin liquid film on the outer surface of the tank and partially evaporates, absorbing heat from the tank to control the cooling rate. The protective atmosphere containing the remediation substrate formed by evaporation fills the functional chamber and exchanges trace amounts of substances with the headspace atmosphere inside the tank through the heat penetration zone at the tank top cover and tank wall seal. The residual heat maintained by the tank during the first cooling stage causes the trace components of the remediation substrate entering the headspace region to condense and flow back to the matrix surface, promoting the repair of sublethal structural damage caused by the immunologically active components.

[0064] By utilizing the interaction between carbon dioxide dissolved in the matrix during the pre-equilibrium phase and residual reducing substances in the matrix, conformational repair of immune-active components can be further promoted.

[0065] When the tank surface temperature drops below the second target temperature, the system switches to the second cooling stage, using conventional cooling media to accelerate cooling to room temperature.

[0066] The tank, cooled to room temperature, is transferred to the curing area of ​​the cleanroom and cured at the preset ambient temperature for the preset time.

[0067] During maturation, the microgel cores in the core-shell dispersion structure shrink and densify. Due to the decrease in temperature during maturation, supersaturated carbon dioxide escapes from the microgel cores, accompanied by shrinkage and densification, forming microporous structures inside and on the surface of the microgel cores, thus constructing a gastrointestinal targeted release structure. This structure remains relatively stable in the acidic environment of the pet's stomach, delaying the premature release of immune-active components; under the neutral to slightly alkaline environment of the intestines and the action of digestive enzymes, the microgel cores gradually disintegrate, releasing the immune-active components.

[0068] After curing, the tank is sampled and tested, including the internal pressure and structural stability. When the internal pressure is within the preset slightly positive pressure range and the structural stability meets the preset conditions, the curing is deemed qualified, and the product proceeds to the packaging or storage process.

[0069] Example 2: The product from Example 1, after maturation and shaping, underwent in vitro simulated digestion assays to obtain the bioavailability of the immunologically active ingredients. A continuous digestion model was constructed using canine and feline gastrointestinal physiological parameters to simulate the gastric and intestinal digestion stages sequentially. After digestion, the micelle phase and residue phase were separated, and the content of the immunologically active ingredients in the micelle phase was determined to calculate the bioavailability.

[0070] The measured bioavailability is compared with a target threshold. When the bioavailability is lower than the target threshold, the deviation is fed back to the preceding steps and the corresponding parameters are corrected. The preceding steps and corresponding correctable parameters include at least one of the following: a preset target value for redox potential pre-adjustment, a shearing parameter for gradient dispersion embedding, and a preset threshold for dynamic switching sterilization. The corrected parameters are applied to subsequent batch production, forming a closed-loop process.

[0071] Example 3: Mousse-like pet food canned food was prepared using the production process of Example 1. The wet food matrix was thoroughly chopped to achieve a uniform texture. The chopping time was extended compared to meat-based products, allowing the immune-active components to be evenly embedded in the microgel core, resulting in a delicate mousse texture. After filling, headspace atmosphere replacement, dynamic switching sterilization, residual heat window-based targeted repair, and maturation were performed sequentially to obtain a mousse-like wet food product that enhances pet immune function.

[0072] Example 4: Meat chunk-shaped pet food canned food was prepared using the production process of Example 1. The wet food matrix contained visible meat chunks, and the chopping time was shorter than that of mousse-like products to preserve the integrity of the meat chunks. Immunologically active ingredients were embedded in the gel layer on the surface of the meat chunks or in microgel particles in the broth, resulting in a product with visible meat chunks. After filling, headspace atmosphere replacement, dynamic switching sterilization, residual heat window-oriented repair, and maturation were performed sequentially to obtain a meat chunk-shaped wet food product that enhances the immune function of pets.

[0073] Example 5: A soup-based pet food canned food was prepared using the production process of Example 1. The moisture content of the wet food matrix was higher than that of the meat block product. Immunologically active ingredients were embedded in microgel particles dispersed in the soup, or attached to a gel layer on the surface of the solid ingredients, giving the product a soup-like form. After filling, the product underwent headspace displacement, dynamic switching sterilization, residual heat window-based targeted repair, and maturation to obtain a soup-based wet food product that enhances the immune function of pets.

[0074] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. A production process for enhancing the immune function of pet food, characterized in that, Includes the following steps: The redox potential of the wet pet food matrix containing immune-active ingredients is pre-adjusted so that the redox potential of the matrix is ​​lower than the critical redox potential of the immune-active ingredients. The immunoactive components are encapsulated in a microgel precursor in a gradient dispersion manner to form a core-shell dispersion structure. The filled tanks undergo headspace displacement and pre-equilibrium treatment to dissolve carbon dioxide in the matrix and create a slightly acidic environment. Based on the feedback of the activity decay rate of the immune active components, sterilization is dynamically switched between the standard sterilization path and the low-temperature long-time compensation path. During the residual heat window after sterilization, the immune-active components are targeted for repair. After maturation and shaping, a wet food product that enhances the immune function of pet food is obtained.

2. The production process for enhancing the immune function of pet food according to claim 1, characterized in that, The redox potential pre-adjustment includes: A reducing agent is added to the matrix, and an inert gas is introduced during the chopping process for bubble deoxygenation. The matrix redox potential is monitored in real time. When the matrix redox potential is lower than the critical redox potential by a preset safety margin, the pre-adjustment is deemed qualified.

3. The production process for enhancing the immune function of pet food according to claim 2, characterized in that, The process of encapsulating immunologically active components in a microgel precursor using a gradient dispersion method includes: The first stage of high-shear treatment involves dispersing gel-forming protein substances in the matrix to form microgel precursors. The second stage of low-shear treatment involves introducing and encapsulating the immunoactive components within the microgel precursor to form the core-shell dispersion structure. The particle size distribution characteristic value of the slurry is monitored online. When the particle size distribution characteristic value is within a preset protection range, the directional dispersion is deemed qualified.

4. The production process for enhancing the immune function of pet food according to claim 3, characterized in that, The headspace atmosphere replacement and pre-equilibrium treatment includes: The filled tanks are subjected to a three-stage gas replacement process: vacuuming, filling with nitrogen to atmospheric pressure, and then filling with carbon dioxide to a preset pressure. After sealing, maintain a preset pre-equilibrium time to allow carbon dioxide to fully dissolve in the matrix and form a slightly acidic environment before proceeding to the sterilization process.

5. The production process for enhancing the immune function of pet food according to claim 4, characterized in that, The dynamic switching sterilization based on activity decay rate feedback includes: In the sterilization platform section and the heat preservation section, the activity decay rate of the immunologically active component is compared with a preset threshold, and the path is selected based on the comparison result: When the activity decay rate is not higher than a preset threshold, the standard sterilization path is maintained; When the activity decay rate is higher than a preset threshold, the system switches to the low-temperature long-term compensation path and simultaneously replenishes the headspace of the tank with inert protective gas.

6. The production process for enhancing the immune function of pet food according to claim 5, characterized in that, The activity decay rate is estimated by real-time monitoring of changes in parameters inside the tank during the sterilization process; The standard sterilization path is to sterilize at a first sterilization temperature and a first holding time, and the low-temperature long-time compensation path is to sterilize at a second sterilization temperature lower than the first sterilization temperature and a second holding time longer than the first holding time, with the equivalent sterilization values ​​being the same. The low-temperature long-term compensation path also includes performing pulsed steam injection during the heat preservation period. The pulsed steam injection is a cyclical operation in which steam is injected into the sterilizer at preset time intervals to raise the temperature instantaneously, and then the pressure is released instantaneously to lower the temperature.

7. The production process for enhancing the immune function of pet food according to claim 6, characterized in that, The targeted repair during the residual heat window after sterilization includes: The cooling rate of the first cooling stage is controlled to be lower than that of the second cooling stage; wherein, the first cooling stage is to reduce the temperature from the sterilization peak temperature to the first target temperature, and the second cooling stage is to reduce the temperature from the first target temperature to room temperature; During the first cooling phase, the residual heat window period is maintained, and / or the carbon dioxide dissolved in the matrix during the pre-equilibrium phase is used in combination with residual reducing substances to promote the repair of sublethal structural damage of immune active components. When the tank surface temperature drops below the second target temperature, switch to the second cooling stage to accelerate cooling.

8. The production process for enhancing the immune function of pet food according to claim 7, characterized in that, Curing and shaping include: Place the container, cooled to room temperature, at the preset ambient temperature for a preset curing time; During the maturation process, the microgel cores in the core-shell dispersed structure shrink and densify. At the same time, due to the decrease in temperature during maturation, the supersaturated carbon dioxide inside the microgel cores escapes. Accompanying the shrinkage and densification of the microgel cores, a microporous structure is formed, thus constructing a gastrointestinal targeted release structure. After the curing process is completed, the pressure inside the tank and the stability of the tank structure are tested. When the pressure inside the tank is within the preset slightly positive pressure range and the structural stability meets the preset conditions, the curing process is deemed qualified.

9. The production process for enhancing the immune function of pet food according to claim 8, characterized in that, Also includes: The product after maturation and shaping was subjected to in vitro simulated digestion assays to obtain the bioavailability of the immune-active components. The biological accessibility rate is compared with a target threshold. When the biological accessibility rate is lower than the target threshold, the deviation is fed back to the preceding steps and the corresponding parameters are corrected. The preceding steps include at least one of the following: a preset target value for pre-adjusting redox potential, a shearing parameter for gradient dispersion and embedding, and a preset threshold for dynamically switching sterilization.

10. The application of a production process as described in any one of claims 1-9 in the preparation of wet food products that enhance pet immune function, characterized in that, The wet food products include mousse-like, meat chunk-like, or soup-based canned pet food.